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Abstract
Aim Genome-wide association studies have identified > 30 common variants associated with Type 2 diabetes (> 5% minor
allele frequency). These variants have small effects on individual risk and do not account for a large proportion of the heritable
component of the disease.Monogenic forms of diabetes are caused bymutations that occur in < 1:2000 individuals and follow
strict patterns of inheritance. In contrast, the role of low frequency genetic variants (minor allele frequency 0.1–5%) in Type 2
diabetes is not known. The aim of this studywas to assess the role of low frequencyPDX1 (also called IPF1) variants in Type 2
diabetes.
Methods We sequenced the coding and flanking intronic regions of PDX1 in 910 patients with Type 2 diabetes and 878
control subjects.
Results We identified a total of 26 variants that occurred in 5.3% of individuals, 14 of which occurred once. Only D76N
occurred in > 1%.We foundnodifference in carrier frequency betweenpatients (5.7%)and control subjects (5.0%) (P = 0.46).
There were also no differences between patients and control subjects when analyses were limited to subsets of variants. The
strongest subset were those variants in the DNA binding domain where all five variants identified were only found in patients
(P = 0.06).
Conclusion Approximately 5% of UK individuals carry a PDX1 variant, but there is no evidence that these variants, either
individually or cumulatively, predispose to Type 2 diabetes. Further studies will need to consider strategies to assess the role of
multiple variants that occur in < 1 in 1000 individuals.
Diabet. Med. 28, 681–684 (2011)
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Introduction
The study of the genetic component to complex diseases such as
Type 2 diabetes has primarily focused on testing common
variants. Genome-wide association studies focus on common
single nucleotide polymorphisms, where common is usually
defined as > 5% minor allele frequency. To date, there are over
30 replicated genome-wide association study case–control
associations with Type 2 diabetes [1–3]. Despite the successful
identification of many common variants involved in Type 2
diabetes, they explain only a fraction of the estimated genetic
component. One possible explanation for this ‘missing
heritability’ is that low frequency variants contribute
substantially to the genetic risk of Type 2 diabetes. Most
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variants in the human genome are of low frequency (< 5%) and
manymore are < 1%frequency. Such low frequency variants are
poorly captured by current genome-wide association study
microarrays. Projects such as the 1000 Genomes Project are
likely to reveal amuch larger set of low frequency variants, but it
remains a challenge to perform adequately powered association
tests of such variants with human phenotypes. Few studies have
tested comprehensively the role of low frequency variants in
Type 2 diabetes, either genome wide or in the context of
candidate genes. One study has tested theWFS1 gene, but found
no associations other than the well-replicated common variant
(rs10010131) [4], and a second study tested part of theHNF1A
gene [5] but did not identify any associated coding variants.
Despite the challenges, there are several proof-of-principle
examples that suggest sequencing strategies will identify low
frequency variants involved in common human traits. These
include the identification of rarer variants in the IFIH1 gene that
protect fromType 1 diabetes [6] and the low frequency variants
inNOD2 thathave strongpredisposingeffectsonCrohnsdisease
[7]. Other approaches have shown that multiple low frequency
coding variants in one or more genes accumulate at the tails of a
population distribution for a continuous trait such as lipid levels
[8] or blood pressure [9].
Mutations in the pancreatic and duodenal homeobox 1
(PDX1 ⁄ IPF1) gene are a known cause of monogenic diabetes
(OMIM 600733).PDX1 is a key transcription factor involved in
pancreatic development, islet hormone expression and the
regulation of insulin in the mature B-cell. The importance of
PDX1 in pancreatic development is highlighted by the knockout
mouse model, which has pancreatic agenesis [10]. This
phenotype is mirrored in humans, where two different families
have been described with pancreatic agenesis and neonatal
diabetes attributable to recessive mutations [11,12].
Heterozygous mutation carriers have a later age of diabetes
onset. PDX1 has been previously studied as a candidate gene
and in genome-wide association studies for Type 2 diabetes, but
these approaches have been limited either to sequencing in
small numbers of patients or common single nucleotide
polymorphisms (genome-wide association studies) and there
have been no robust associationswith diabetes risk. In this study,
we used an extensive re-sequencing approach to test the role in
Type 2diabetes of a comprehensive set of low frequencyand rare
PDX1 variants.
Subjects and methods
Case–control cohort
The study population consisted of 910 patients with Type 2
diabetes. We selected patients diagnosed under 55 years, not
insulin treated within the first year of diagnosis, with a median
age of onset of 43 years (range 17–55 years) and a median BMI
of 31 kg ⁄m2 (range 18–58 kg ⁄m2). The control population
consisted of 878 normoglycaemic individuals, who were not
known to have diabetes at time of blood collection, defined by a
fasting blood glucose of < 5.5mmol ⁄ l and ⁄or HbA1c < 7%
(< 53 mmol ⁄ml). This population had amedian age at sampling
of 35 years (range 17–86 years) and amedian BMI of 26 kg ⁄m2
(range 17–49 kg ⁄m2). All participants (patients and control
subjects) were from the South West region of the UK and of
European ancestry and came from four sample collections: the
Exeter Family Study (control subjects), the Young Type 2
diabetes Study (YTYPE 2 DIABETES) and the Diabetes in
Families Study (Warren2).
Sequencing methods
We screened the two exons and approximately 50 bp of flanking
sequence of the PDX1 gene using bidirectional sequencing using
standard conditions and following manufacturers’ protocols
(primers available on request). Sequencing reactions were run
on an ABI3730 capillary machine (Applied Biosystems,
Warrington, UK). Sequencing was viewed in Mutation
Surveyor (SoftGenetics, State College, PA, USA) (PDX1
nucleotide reference NM 000209.3).
We used the bioinformatic tools, SIFT, PolyPhen and
MutationTaster (http://blocks.fhcrc.org/sift/SIFT_dbSNP.html,
http://genetics.bwh.harvard.edu/pph/, http://www.mutationtaster.
org/)to predict the effect novel variantswould have on the PDX1
protein (protein reference NP 000200.1).
Statistical comparison
To compare the prevalence of individual variants and
accumulations of variants in patients with Type 2 diabetes vs.
control subjects, we used Fisher’s exact test.We had 80%power
to detect variants that occurred in one control subject and seven
patients with Type 2 diabetes at nominal levels of significance
(P = 0.05)
Results
Molecular genetics
We sequenced 1788 individuals and identified 26 low frequency
and rare variants in the PDX1 gene. The detailed distribution of
these variants within the cases and controls is shown in Table 1.
Of these 26 variants, 22 were in the coding region, of which 17
altered the amino acid sequence, four were in the sequence
immediately flanking the exons and 18were novel (Table 1). Six
of the variants were predicted likely to be deleterious in at least
two bioinformatic programs, with three variants (P99H, E160V
and R198C) predicted to be damaging by all three programs.
Association with diabetes
Individual rare variant analysis
For each of the 26 rare variants, there was no significant
difference in frequency between patients and control subjects.
Only one variant, D76N, occurred in more than 1% of
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individuals and was not associated with Type 2 diabetes (12
patients vs. 11 control subjects, P = 0.83).
Accumulation of low frequency variants in the PDX1 gene
We found that 5.3% of all individuals carried a variant in the
PDX1 gene, with no difference between patients (5.7%) and
control subjects (5%) (P = 0.46). There were no differences
between patients and control subjects when we carried out
subgroup analysis comparing missense and frameshift variants
(42 patients vs. 33 control subjects, P = 0.55), or variants that
were unique to either patients or control subjects (13 vs. 5,
P = 0.09), or unique to either patients or control subjects and in
the coding region (8 vs. 3, P = 0.22). We considered those
predicted to be deleterious by at least two bioinformatic
programs and there was no significant difference (37 patients
vs. 32 control subjects, P = 0.70). Finally, there were no
differences when limiting the analyses to those variants in the
DNA binding domain (137–203 amino acids), although all five
variants identified in this regionwere in thepatients (5patientsvs.
0 control subjects, P = 0.06).
In a secondary analysis, the 5.7%ofpatients carrying a variant
were leaner [28.3 kg ⁄m2 (18–44 kg ⁄m2)] compared with
patients not carrying a variant [31.3 kg ⁄m2 (18–58 kg ⁄m2)]
(P = 0.002), but not diagnosed earlier (P = 0.15).
Discussion
The identification of gene variants associated with Type 2
diabetes but not captured by current genome-wise association
studies is important for twomain reasons. First, such variants are
likely to be of low frequency and may have appreciably greater
effects on individual risk than the common variants typically
identified by genome-wise association studies. Second, if such
variants alter the coding sequence of genes, they could implicate
the gene’s protein product in the aetiology of diabetes.
Our study representsoneof fewattempts to sequence the entire
coding sequence of a known diabetes gene in more than a
thousand individuals and test the individual and cumulative
variants for association with Type 2 diabetes. Our results are
analogous with those of Fawcett et al. [4], who showed that a
large number of low frequency variants occur in the Wolfram
syndrome gene, WFS1, but there is no evidence that these
variants influence the risk of Type 2 diabetes. Eight per cent of
UK individuals carry a low frequency variant in theWFS1 gene
Table 1 PDX1 rare variants identified in 910 patients with Type 2 diabetes and 878 control subjects
Position of change AA change
Case subjects
(n = 910)
Control subjects
(n = 878) Nucleotide change
SIFT ⁄ PolyPhen ⁄
MutationTaster
*c.1-25insCTCCCGG 1 1 c.-25 NA
*2 N 3 3 c. 6 C > T NA
*3 G > A 1 0 c. 8 G > C ) ⁄ + ⁄ )
18 C > R 0 1 c. 52 T > C + ⁄ ++ ⁄ )
*33 P 2 1 c. 97 T > C ⁄T > A NA
33 P > T 6 5 c. 97 C > A + ⁄ ++ ⁄ +
*55 G 1 3 c. 165 C > A NA
76 D > N 12 11 c. 226 G > A + ⁄ ) ⁄ +
*95 P > Q 1 0 c. 284 C > A ) ⁄ ) ⁄ +
*96 P > S 0 1 c. 286 C > T ) ⁄ ++ ⁄ )
*99 P > H 1 1 c. 296 C > A + ⁄ ++ ⁄ +
*117 L > M 1 0 c. 349 C > A + ⁄ ) ⁄ +
140 A > T 2 0 c. 418 G > A ) ⁄ ) ⁄ )
143 P > R 1 0 c. 428 C > G + ⁄ + ⁄ +
*160 E > V 1 0 c. 479 A > T + ⁄ ++ ⁄ +
197 R > H 1 0 c. 590 G > A + ⁄ + ⁄ +
*198 R > C 2 0 c. 592 C > T + ⁄ ++ ⁄ +
239 P > Q 8 10 c. 716 C > A ) ⁄ ++ ⁄ +
*242 P > L 4 3 c. 725 C > T ) ⁄ ++ ⁄ +
P243insPro(GCC) 1 0 c. 726 insGCC NA
*245 G > R 0 1 c. 733 G > A + ⁄ + ⁄ )
*250 P 0 2 c. 750 C > A NA
*264 G 1 0 c. 792 C > T NA
*IVS1 + 1 (c.406 + 1G > C) 1 0 c. 406 + 1 G > C NA
*IVS2 – 8 (c.407 – 8G > T) 0 1 c. 407 – 8 G > T NA
*IVS2 + 4 (c.846*4G > A) 1 0 c. 846 + 4 G > A NA
*Novel variant.
SIFT ⁄ PolyPhen ⁄MutationTaster: ) tolerated, + not tolerated (SIFT) ⁄ ) benign, + possibly damaging, ++ probably damaging (PolyPhen) ⁄ )
polymorphism, + disease causing (MutationTaster) (http://blocks.fhcrc.org/sift/SIFT_dbSNP.html, http://genetics.bwh.harvard.edu/pph/,
http://www.mutationtaster.org/).
AA, amino acid; NA, not applicable.
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and 5% carry a low frequency variant in the PDX1 gene.
Furthermore, the PDX1 variant D76N has been widely studied,
but the reproducibility of associationswithType 2 diabetes have
varied [13–18]. Our data are in keeping with the recent meta-
analysis of PDX1 D76N case–control studies concluding that
there is no association with Type 2 diabetes [19].
Together with theWFS1 study, our results have a number of
implications for the study of rarer genetic variation in diabetes.
First, the results suggest that a largeproportionof codingvariants
will be present at a low frequency, with all but one of the 26
variants we identified in PDX1 in less than 1% of individuals.
Such variants will need to confer odds ratios of 1.8 (for 1%
frequency) to 4.5 (for 0.1% frequency) to be detectable at
P = 5 · 10)8 in 10 000 patients with Type 2 diabetes and
10 000 control subjects. Second, 14 of these variants occurred
only once in all 1788 individuals. This distribution of allele
frequencies means that testing the cumulative effects of multiple
low frequency coding variants could be used to potentially
improve power. The power of such cumulative tests will depend
on the proportion of variants that have a functional effect.
Alternatively, studies of low frequency and rare variants should
consider tracking variants through families and performing tests
of linkage with reduced penetrance. The analysis of PDX1 in
further samples, and possibly functional studies, will strengthen
the evidence for or against the role of coding variants specific to
the DNA-binding domain of PDX1, where we found variants in
five individuals with diabetes and none in control subjects.
Finally, genome-wide analysis of low frequency variants in large
sample populationsmay provide additional insights into the role
of low frequency variants in Type 2 diabetes.
In conclusion, our study has shown that PDX1 is an excellent
candidate to capture low frequencyvariants; however, there is no
evidence that these variants, either individually or cumulatively,
predispose to Type 2 diabetes.
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